These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 18278577)

  • 1. Cholera toxin structure, gene regulation and pathophysiological and immunological aspects.
    Sánchez J; Holmgren J
    Cell Mol Life Sci; 2008 May; 65(9):1347-60. PubMed ID: 18278577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulation using bacterial enterotoxins.
    Simmons CP; Ghaem-Magami M; Petrovska L; Lopes L; Chain BM; Williams NA; Dougan G
    Scand J Immunol; 2001 Mar; 53(3):218-26. PubMed ID: 11251877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholera toxin - a foe & a friend.
    Sanchez J; Holmgren J
    Indian J Med Res; 2011 Feb; 133(2):153-63. PubMed ID: 21415489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADP-ribosylating enterotoxins as vaccine adjuvants.
    Lycke N; Lebrero-Fernández C
    Curr Opin Pharmacol; 2018 Aug; 41():42-51. PubMed ID: 29702466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal vaccines based on the use of cholera toxin B subunit as immunogen and antigen carrier.
    Lebens M; Holmgren J
    Dev Biol Stand; 1994; 82():215-27. PubMed ID: 7958476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholera toxin, E. coli heat-labile toxin, and non-toxic derivatives induce dendritic cell migration into the follicle-associated epithelium of Peyer's patches.
    Anosova NG; Chabot S; Shreedhar V; Borawski JA; Dickinson BL; Neutra MR
    Mucosal Immunol; 2008 Jan; 1(1):59-67. PubMed ID: 19079161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
    Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S
    Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune modulation by the cholera-like enterotoxins.
    Salmond RJ; Luross JA; Williams NA
    Expert Rev Mol Med; 2002 Oct; 4(21):1-16. PubMed ID: 14585161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
    Holmgren J; Harandi AM; Czerkinsky C
    Expert Rev Vaccines; 2003 Apr; 2(2):205-17. PubMed ID: 12899572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholera toxin and related enterotoxins as potent immune modulators.
    Hirst TR; Nashar TO; Pitman RS; Williams NA
    Symp Ser Soc Appl Microbiol; 1998; 27():26S-34S. PubMed ID: 9750359
    [No Abstract]   [Full Text] [Related]  

  • 11. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants.
    Pizza M; Giuliani MM; Fontana MR; Monaci E; Douce G; Dougan G; Mills KH; Rappuoli R; Del Giudice G
    Vaccine; 2001 Mar; 19(17-19):2534-41. PubMed ID: 11257389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetically manipulated bacterial toxin as a new generation mucosal adjuvant.
    Yamamoto M; McGhee JR; Hagiwara Y; Otake S; Kiyono H
    Scand J Immunol; 2001 Mar; 53(3):211-7. PubMed ID: 11251876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LTK63 and LTR72, two mucosal adjuvants ready for clinical trials.
    Pizza M; Giuliani MM; Fontana MR; Douce G; Dougan G; Rappuoli R
    Int J Med Microbiol; 2000 Oct; 290(4-5):455-61. PubMed ID: 11111926
    [No Abstract]   [Full Text] [Related]  

  • 14. Cholera-like enterotoxins and Regulatory T cells.
    Basset C; Thiam F; Martino CD; Holton J; Clements JD; Kohli E
    Toxins (Basel); 2010 Jul; 2(7):1774-95. PubMed ID: 22069660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of ADP-ribosylation and G(M1)-binding activity in the mucosal immunogenicity and adjuvanticity of the Escherichia coli heat-labile enterotoxin and Vibrio cholerae cholera toxin.
    de Haan L; Verweij W; Agsteribbe E; Wilschut J
    Immunol Cell Biol; 1998 Jun; 76(3):270-9. PubMed ID: 9682971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial to evaluate safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli prototype vaccine containing CFA/I overexpressing bacteria and recombinantly produced LTB/CTB hybrid protein.
    Lundgren A; Leach S; Tobias J; Carlin N; Gustafsson B; Jertborn M; Bourgeois L; Walker R; Holmgren J; Svennerholm AM
    Vaccine; 2013 Feb; 31(8):1163-70. PubMed ID: 23306362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of the immune response by the cholera-like enterotoxins.
    Plant A; Williams NA
    Curr Top Med Chem; 2004; 4(5):509-19. PubMed ID: 14965302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges.
    Holmgren J; Czerkinsky C; Eriksson K; Mharandi A
    Vaccine; 2003 Jun; 21 Suppl 2():S89-95. PubMed ID: 12763689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clostridium difficile toxin A carboxyl-terminus peptide lacking ADP-ribosyltransferase activity acts as a mucosal adjuvant.
    Castagliuolo I; Sardina M; Brun P; DeRos C; Mastrotto C; Lovato L; Palù G
    Infect Immun; 2004 May; 72(5):2827-36. PubMed ID: 15102793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cloning, expression and identification of Escherichia coli LTB gene and Vibrio cholerae CTB gene].
    Xia XP; Yan J; Zhao SF
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2003 Feb; 32(1):17-20. PubMed ID: 12640703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.